The Global Still’s Disease Treatment Market Continues to Grow Owing To the Rising Cases of Osteoarthritis in the World Along With New Drug Launches

Still’s disease treatment is administered to people going through the condition. Still's a disease or Inflammatory arthritis is a rather serious form of arthritis that features joint and fever-like symptoms. In some people, however, still's disease progresses or reoccurs after treatment. This inflammation may destroy healthy joints, especially the hands. Treatment usually includes medications, including prednisone, which helps control inflammation. Some people need more aggressive treatment with steroid tablets or oral steroids, while others require surgery to remove infected tendons. Still's disease tends to run in families and tends to be more common in women than in men.

Juvenile Idiopathic Arthritis is a less severe form of still's disease and is characterized by severe fevers, joint pain, and swelling. Often, these symptoms do not appear until after the disease has progressed into osteoarthritis. If it is caught early enough, it can be controlled. There are still researchers looking at why some forms of inflammatory arthritis progress while others do not. They are studying patients with juvenile idiopathic arthritis, a genetic disorder, in order to find a cure for the disease.

The increasing number of osteoarthritis cases in the world is the main factor that is driving the growth of the global Still’s disease treatment market. For instance, according to Healio, in 2020 the global cases of knee and hip osteoarthritis cases has exceeded 300 million. Moreover, increasing product launches and market strategies by key market players is another main factor that is augmenting the growth of the global Still’s disease treatment market.

Inflammatory arthritis can also be treated with medications that, as well as helping to control the symptoms, help patients' joints to heal. Anti-inflammatory medications are often taken to reduce swelling in the joints and help to relieve the pain from arthritis symptoms. Corticosteroids, which work to shrink swollen and inflamed joints, are commonly used. While these medications can be used initially to help ease the symptoms, patients usually have to take them for life in order to prevent the disease from recurring. However, the high treatment cost of Still's disease is the main restraining factor that is hindering the growth of the global Still’s disease treatment market.

Owing to the increase of osteoarthritis cases in the region, North America is witnessing high demand in the global Still’s disease treatment market. For instance, according to Osteoarthritis Action Alliance, the Centers for Disease Control and Prevention expects that there are more than 54.4 million adults in the region suffering from some form of arthritis. Moreover, increasing initiatives to raise awareness about arthritis is also enhancing the growth of the global Still’s disease treatment market. Owing to such factors there have been several developments in the global Still’s disease treatment market. For instance, in July 2019, AstraZeneca and Aevi Genomic Medicine started a licensed contract, in order to carry out MEDI2338’s phase II trials. MEDI2338 is a human mAb, which targets IL-18.